The Life Sciences Report
Notable Quotes
"CYTR's preclinical data for aldoxorubicin has been very supportive, and its phase 1b/2 trial has shown quite promising, albeit early stage, efficacy." (6/13/13) CytRx Corp. - The Life Sciences Report Interview with Michael Aikenhead More >
"ATHX is an exciting story and definitely a company to watch." (6/6/13) Athersys Inc. - The Life Sciences Report Interview with Christian Glennie More >
"NEO has been able to continue to grow the topline nicely and maintain margins of more than 45%." (5/30/13) NeoGenomics Laboratories - The Life Science Report with Kevin DeGeeter More >
"OPK's 4Kscore is approved in Europe and should be approved in the U.S. sometime in 2013." (5/30/13) OPKO Health Inc. - The Life Science Report with Kevin DeGeeter More >
"CTH is very early in the game with a very good and relatively derisked idea." (5/30/13) Cynapsus Therapeutics Inc. - The Life Science Report with Ori Hershkovitz More >
Companies
| Last: | |||
| Change: | Change(%): | ||
| Volume: | Open: | ||
| High: | Low: | ||
| 52Wk High: | 52Wk High: | ||
Experts Commenting on This Company
|
Oncolytics Biotech Inc.TICKER: ONCY:NASDAQ; ONC:TSXOncolytics Biotech Inc. is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The company is conducting clinical studies using Reolysin, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. Oncolytics' clinical program includes a number of human trials at a variety of stages including a phase 3 trial in head and neck cancers. The company has advanced its product manufacturing and intellectual property initiatives parallel to its clinical development program to support development of a commercial product. |
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Expert Comments:
Wang Chong, Edison Investment Research (6/14/13) "Oncolytics Biotech Inc. has announced promising preliminary phase 2 melanoma and lung cancer data. However, in view of the rapidly evolving treatment landscape in this poorly treated indication, the company has pragmatically decided to re-evaluate Reolysin in combination with the new and increasingly targeted immunotherapies before conducting the next melanoma clinical trial; by contrast, Oncolytics will be conducting further trials in squamous cell carcinoma of the lung following the recent positive data."
Douglas Loe, Byron Capital Markets (5/23/13) "Oncolytics Biotech Inc. provided interim analysis of its 43-patient phase 1/2 open-label malignant melanoma trial, assessing tumor response in patients treated with oncolytic reovirus formulation Reolysin in combination with paclitaxel/carboplatin. . .data from 14 evaluable patients were certainly positive, at least to the limits of study design, with 71.5% of patients experiencing either a partial tumor response or stable disease. . .Oncolytics' Reolysin clinical pipeline has expanded materially in recent quarters and now includes several randomized, controlled phase 2 cancer trials, many in collaboration with the Canadian NCI's Clinical Trials Group, for which we expect more direct evidence of Reolysin anticancer activity in comparison to alternative therapies."
Neil Maruoka, Canaccord Genuity (5/9/13) "Based on recent evidence of efficacy for Reolysin, we would be buyers of Oncolytics Biotech Inc. stock in anticipation of more impactful data from the head and neck trial and the phase 2 study in pancreatic cancer, both expected within the next six months. . .the company is cashed up: It ended the quarter with cash and equivalents of $43.5M. We believe this represents almost 18 months of cash at projected burn."
Philippa Flint, Bloom Burton & Co. (5/9/13) "Oncolytics Biotech Inc.'s Reolysin phase 3 head and neck survival data are now expected in H2/13. . .at that time, we believe we may see data on the primary endpoint of survival, but also we expect to see progression free survival and tumor response. . .the company recently raised net proceeds of $30.2M, enabling it to carry on operations regardless of the outcome of the phase 3 study."
Douglas Loe, Byron Capital Markets (3/28/13) "Signals on disease stabilization are still strong for Oncolytics Biotech Inc.'s Reolysin in an ongoing open-label lung cancer trial. . .the company provided another interim analysis of its ongoing 55-patient phase 1/2 open-label advanced squamous cell lung cancer trial showing a disease control rate (adding together all patients exhibiting complete tumor response, partial tumor response, and those with stable disease) of 86% in 21 evaluable subjects. . .the data is thus highly similar to prior analyses, differing mostly by observing that Reolysin responsiveness was sustained beyond earlier time points. . .we maintain our Speculative Buy rating and $8 target price."
